Page 71 - Priority Review News Today

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective...

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective...

Nine analysts raise stock price targets for Apellis Pharmaceuticals after it wins the FDA's first approval for a geographic atrophy therapy.

The FDA has accepted for Priority Review the NDA for ADX-2191 (methotrexate injection) for primary vitreoretinal lymphoma.

The FDA’s panel voted in favor of GSK’s RSV vaccine candidate for active immunization to prevent RSV-associated lower respiratory tract disease in older adults.

LONDON (dpa-AFX) - The US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of GSK plc's (GSK,GSK.L) respiratory syncytial virus

 Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver...

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)

Investegate announcements from Ipsen Pharma, Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic...